Probiotics in the Management of Atopic Dermatitis for Children: A Case-Based Review

Table 3

Importance appraisal of RCTs based on CEBM critical appraisal tools.

Importance
Author	Parameters for efficacy endpoints	MCID	Mean total SCORAD score in the probiotic group at the trials’ endpoint ± SD (CI 95%)	Mean total SCORAD score in the placebo group at the trials’ endpoint ± SD (CI 95%)	Mean difference between the two groups (probiotic-placebo) (CI 95%)	Comments
Navarro-Lopez et al. [15]	SCORAD^a	8.7	6.8	24.4	17.8^b	The mean difference between the two groups achieved MCID
Prakoeswa et al. [16]	SCORAD^a	8.7	18.53 ± 14.200	22.04 ± 8.817	3.507 ± 4.96 (95% CI 1.44 to 5.58)	The mean difference between the two groups did not achieve MCID
Yang et al. [17]	EASI^a and VASP	6.6 for EASI and N/A for VASP	4.7 ± 3.4 (EASI) and 3 (VASP)^c	4.5 ± 4.7 (EASI) and 2.5 (VASP)^c	−0.2 ± 0.86 (95% CI, −1.74 to 2.14 for EASI)^d	Mean difference between the two groups did not achieve MCID
Woo et al. [18]	SCORAD^a	8.7	28.8 ± 11.92 (25.1–32.4)	35.8 ± 11.75 (31.9–39.8)	−7 ± 22.98 (95% CI, −12.2 to −1.8)	Mean difference between the two groups did not achieve MCID
Han et al. [19]	SCORAD^a	8.7	20.4 ± 11.8 (16.9 to 23.9)	25.6 ± 11.6 (22.0 to 29.2)	−5.2 ± 27.93 (95% CI, −10.24 to −0.16)	Mean difference between the two groups did not achieve MCID

^aMCID for these studies was obtained from a study that measured the MCIDs of SCORAD, EASI, and POEM for atopic eczema by Schram et al. [14]. ^bData were not adequate to calculate the confidence interval. ^cResult was reported using a nonparametric statistic, and no confidence interval was reported. Converted result into parametric data was retrieved from a systematic review [15]. ^dMean reduction between two groups was extracted from a systematic review that had transformed the result into parametric data beforehand. MCID for VASP that is specific for eczema has never been investigated [1].